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Summary
 
Establishment of antigen-specific tolerance among mature T cells has been a long debated, yet
poorly understood issue. In this study we have used transgenic mice bearing a class II–restricted
TCR specific for the hemmagglutinin of the influenza virus in order to test the behavior of
CD4
 
1
 
 T cells upon exposure to antigen in different forms and doses. We first studied the fate
of T cells expressing the transgenic TCR (6.5) in double transgenic mice where HA was ex-
pressed as a self antigen by hemapoietic cells. In these mice, we found some mature T cells in
periphery that had escaped thymic deletion and that showed signs of activation but which were
anergic. Mature CD4
 
1
 
6.5
 
1
 
 cells that were transferred into antigen-containing recipients went
through an initial phase of expansion after which most cells were deleted and those remaining
became unresponsive, as previously described for CD8
 
1
 
 cells. Inducing tolerance in CD4
 
1
 
6.5
 
1
 
cells in situ in single transgenic mice proved a difficult task: classical protocols using single doses
of soluble or deaggregated antigen as well as feeding antigen all failed to induce antigen-specific
unresponsiveness. It was only after decreasing cell numbers by CD4 antibody treatment and by
repeatedly reintroducing antigen thereafter that unresponsiveness of 6.5
 
1
 
 cells was achieved
and maintained. In no case could we observe the appearance of antigen-specific T cells with a
Th2 cytokine profile among the remaining cells and therefore conclude that deletion and an-
ergy represent the major mechanisms of tolerance in our studies. 
 
S
 
elf-nonself discrimination of the immune system is in
part due to an intrinsic difference in response to antigen
of immature versus mature T lymphocytes: self antigens that
are permanently present in the thymus delete immature T
cells by apoptosis while more mature T cells that have not
encountered their antigen during development can respond
in different ways that range from activation to effector func-
tion to the induction of non-responsiveness. The precise
mechanisms of unresponsiveness of mature T cells are still
poorly understood but it has been shown that they may in-
volve deletion (1, 2) or anergy (3–5). Other means in
which regulatory T cells can interfere with certain effector
functions have been proposed (6, 7) but here the evidence
is more indirect and the mechanisms that may involve reg-
ulation through cytokines need to be established in detail.
Induction of tolerance in mature T cells has for years
been attempted in many different ways also because of the
potential applications in organ-specific autoimmune dis-
eases and transplantation. In these studies tolerance could
be achieved by injecting mice with high doses or low doses
of soluble antigen, for instance with deaggregated immu-
noglobulin (8, 9, for review see reference 10). In other
studies unresponsiveness was achieved by feeding antigen
and thus was named oral tolerance (11, for review see ref-
erence 12). Some of the proceedings gave however erratic
results and there is still no procedure which reproducibly
induces specific tolerance to a variety of different antigens
that can be used to interfere with allergy, autoimmunity or
transplant rejection. This may be so because in the more
ancient experiments one could not study the mechanisms
of tolerance because it was difficult to follow the fate of the
antigen-specific cells after the attempted tolerization. More
recent studies that employed mice with transgenic T cell
receptors came to the conclusion that CD8
 
1
 
 T cells specific
for conventional antigen could either be deleted or aner-
gized after a transient period of activation, depending on
the doses of antigen (13). Studies with CD4
 
1
 
 cells specific
for superantigens showed also that many CD4
 
1
 
 T cells un-
derwent apoptotic cell death after activation by the super-
antigen (14). Since superantigens can bind to T cell recep-
tors in a different way than conventional antigens without
direct contact between the TCR and superantigen binding
MHC molecules, it was not clear whether these results
could be extrapolated to CD4
 
1
 
 T cells recognizing con-
ventional antigens. In mice expressing transgenic TCRs on
CD4
 
1
 
 T cells tolerization even with high doses of peptide
failed while it appeared that, upon adoptive transfer, smal-
ler numbers of CD4
 
1
 
 T cells could be tolerized by peptide
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(15), suggesting that the frequency of reactive T cells versus
the amount of antigen could be an important parameter in
the induction of certain forms of tolerance. Here we are re-
porting studies on TCR transgenic mice that express on
CD4
 
1
 
 but also on some CD8
 
1
 
 cells a receptor specific for
peptide 111-119 from influenza hemagglutinin (HA)
 
1
 
 pre-
sented by E
 
d
 
 MHC molecules (16). The transgenic recep-
tor can be identified by a monoclonal anti-idiotypic anti-
body (6.5) and in the various transgenic mice the receptor
is expressed on 
 
z
 
7–10% of all CD4
 
1
 
 T cells in secondary
lymphoid organs. Although this frequency of antigen-spe-
cific cells is high in comparison to the frequency of T cells
specific for conventional non-MHC antigens (10
 
2
 
4
 
), it is
about in the same range as the frequency of T cells re-
sponding to a foreign MHC haplotype.
In these mice we analyzed various ways of antigen pre-
sentation that had the specific goal to tolerize CD4
 
1
 
 T
cells. We first studied tolerance under conditions in which
the antigen was expressed by hemopoietic cells under con-
trol of the Ig-
 
k
 
 promoter. Having obtained evidence that
under these conditions immature as well as mature CD4
 
1
 
T cells can be tolerized, we attempted to define protocols
that employed soluble antigen in various forms to tolerize
mature CD4
 
1
 
 T cells in situ. Our results indicate that
CD4
 
1
 
 cells at a relatively high frequency are extremely dif-
ficult to tolerize in situ unless one employs strategies that
reduce their number and/or responsiveness before antigen
is introduced.
 
Materials and Methods
 
Mice.
 
TCR transgenic (6.5) mice already described (16) ex-
press a T cell receptor 
 
a
 
/
 
b
 
 specific for peptide 111-119 from in-
fluenza hemmagglutinin presented by I-E
 
d
 
. Phenotyping of off-
spring was done by FACS
 
Ò
 
 staining of PBLs with the clonotypic
antibody. For the experimental protocols, heterozygous TCR
transgenic mice between 6 and 10 wk of age were used. Mice ex-
pressing hemagglutinin (HA
 
1
 
) have the HA transgene under con-
trol of the Ig 
 
k
 
 promoter and enhancer elements (Rolink A., not
published) and are on Balb/c background. Transgene expression
was determined by tail DNA PCR using HA primers. Balb/c
mice were obtained from IFFA CREDO (France).
 
Antigen Administration Protocols.
 
The peptide (SVSSFERFE-
IFPK) was synthesized in the Basel Institute for Immunology.
The chimeric immunoglobulin HA-Ig contains the peptide 111-
119 of HA in the CDR3 region of the heavy chain as already de-
scribed (17), and was prepared from the hybridoma supernatant
cultured in complete IMDM 
 
1
 
 3% FCS previously run over a
protein G column (Fast Flow; Pharmacia LKB, Upsala, Sweden).
The antigen was administered by oral route by gastric intuba-
tion with a gauge needle. Intravenous injections were done by
the lateral tail-vein. All the reagents were diluted in sterile PBS
before administration.
In the protocols using the CD4 antibody plus the HA-Ig pro-
tein, one first dose (50 
 
m
 
g) of YTA3.1.2 was injected i.v. the first
day and the same dose of YTA3.1.2 plus 0.1 mg of HA-Ig were
injected the second day.
 
Antibodies and FACS
 
Ò
 
 Analysis.
 
Hybridoma supernatants con-
taining mAbs YTA3.1.2 (18) or 6.5 (anti-clonotypic antibody de-
scribed before [15]) were purified by protein G (Fast Flow) affin-
ity chromatography. 6.5 mAb was labeled using fluorescein succinyl
ester (FLUOS) (Boehringer Mannheim, Mannheim, Germany)
according to the manufacturer’s instructions.
The following mAbs were used: FLUOS-labeled 6.5 mAb,
anti CD8-red613 (GIBCO BRL, Gaithersburg, MD), anti-CD4PE
(Becton Dickinson and Co., Mountain View, CA), biotin-conju-
gated anti-CD69 (PharMingen, San Diego, CA), biotin-conju-
gated anti-CD25 (PharMingen), biotin-conjugated anti-CD45RB
(PharMingen), anti-CD62L (Mel 14, kind gift of F. Lepault), SA-PE
(Southern Biotechnology Associates Inc., Birmingham, AL) and
mouse anti-rat 
 
k
 
-PE (Sigma Chem. Co., St. Louis, MO). Two-
and three-color flow cytometry was performed on FACScan
 
Ò
 
(Becton Dickinson and Co.). Stainings were done in 96-well
plates (5 
 
3 
 
10
 
5
 
 cells per well) in 10-20 
 
m
 
l of mAb at optimal dilu-
tion in PBS 
 
1
 
 5% FCS 
 
1
 
 0.1% azide. Between first and second
step reagents cells were washed in 250 
 
m
 
l of PBS 
 
1
 
 5% FCS 
 
1
 
0.1% azide as was done after the last step. Data (5 
 
3
 
 10
 
4
 
 events)
were stored and analyzed with the LYSIS II software (Becton
Dickinson and Co.).
 
T Cell Proliferation and Cytokine Assays.
 
All in vitro assays were
performed in complete IMDM (
 
b
 
-mercaptoethanol [5 
 
3 
 
10
 
2
 
5
 
M]
penicillin [100 UI/ml]) supplemented with 10% FCS. Responder
cells were isolated from the spleen and lymph nodes and depleted
of B cells with the help of a sheep anti–mouse IgG (H
 
1
 
L) (Biosys,
France) pre-coated on a petri dish at 10 
 
m
 
g/ml. T cells (2 
 
3 
 
10
 
5
 
/
well) were then cultured with 5 
 
3 
 
10
 
5
 
 irradiated (2,200 rads)
Balb/c splenocytes in the presence of 10 
 
m
 
g/ml, 1 
 
m
 
g/ml of pep-
tide, coated 6.5 mAb (100 
 
m
 
g/ml), or medium alone. Exogenous
IL2 was added in some cases, at 30 UI/ml. 
 
3
 
H-incorporation was
measured over the last 18 h of a 66 h culture. Proliferation assays
were done for both spleen T cells and lymph node T cells and
since they gave similar results, only the former are shown. The
supernatant of a 66 h culture in the same conditions as for the
proliferation but containing 4 
 
3 
 
10
 
5 
 
T spleen cells, was collected
and used for ELISA assay. The standards used permitted the de-
tection in the supernatant of a minimum concentration of 150
pg/ml for IL4 and of 600 pg/ml for IFN-
 
g
 
. The antibodies used
were mAb AN-18.17 and biotin-conjugated R4-6A2 for IFN-
 
g
 
(ATCC HB-170), and 11B11 and biotin-conjugated BVD6-24G2
for IL4 (PharMingen). Horseradish peroxidase streptavidin (VEC-
TOR Laboratories, Inc. Burlingame, CA) activity was revealed
by 
 
O
 
-phenylenediamine dihydrochloride substrate (Sigma Chem.
Co.). Plates were read at 490 nm.
 
Transfer Experiments.
 
For the transfer of 6.5
 
1
 
 
 
cells into HA
 
1
 
transgenic recipients, lymph node cells from 6.5
 
1
 
/
 
1
 
RAG2
 
2
 
/
 
2
 
mice were washed and resuspended in serum-free medium. 2.5
 
 3
 
10
 
6
 
 cells were injected into previously irradiated (500 rads) HA
 
1
 
transgenic mice or HA
 
2
 
 
 
littermates. Recipients were killed and
analyzed 4, 8, 14, and 30 d after the transfer.
 
Results
 
Tolerance of CD4
 
1
 
 Cells in Mice that Express the Antigen on
Hemopoietic Cells.
 
We first analyzed the fate of class II re-
stricted cells in double transgenic mice where the antigen
would be constantly present at relatively high concentra-
tions both in the thymus and in the periphery. For that
 
1
 
Abbreviations used in this paper:
 
 FLUOS, fluorescein succinyl ester; HA,
hemagglutinin. 
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purpose, 6.5
 
1
 
 TCR transgenic mice were crossed to mice
transgenic for the HA gene under control of the immuno-
globulin 
 
k
 
 promoter. In the latter mice the antigen is ex-
pressed on hemopoietic cells and their spleen cells stimulate
a good response of unprimed T cells bearing the transgenic
TCR. In double transgenic mice (HA
 
1
 
6.5
 
1
 
), the absolute
number of thymocytes was about half that of HA
 
2
 
6.5
 
1
 
 lit-
termates and, as shown in Fig. 1, the percentage of 6.5
 
1
 
thymocytes among the CD4
 
1
 
CD8
 
2
 
 and CD4
 
2
 
CD8
 
1
 
 sub-
populations was drastically decreased. Note that in periph-
Figure 1. 6.51 cells in the thymus,
lymph nodes and spleen of HA26.51
and HA16.51 mice. Total cell numbers
(3107) for the single and double trans-
genic mice were 6.7 and 3.8 in the thy-
mus, 6.0 and 12.0 in the lymph nodes
and 13.0 and 8.0 in the spleen, respec-
tively. Single cell suspensions were used
for three-color staining with CD4,
CD8, and 6.5 antibodies and 5 3 104
events were stored and analyzed. In this
and all experiments, the marker for the
6.5high expressing cells in periphery was
established according to the level of 6.5
expression by the CD41 thymocytes of
single TCR transgenic mice. 
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eral lymphoid tissue 6.51 cells express less of the transgenic
receptor than thymocytes. This is in part due to the fact
that the peripheral T cells in these mice express in general
slightly lower TCR levels as judged by staining with the
TCR-b antibodies and analysis of RAG2/26.51 mice and
in part due to the fact that 6.51 cells in the transgenic mice
express endogenous TCR-a chains (not shown). The per-
centages of double-negative, double-positive, and single-
positive thymocytes were not very different from that of
HA transgene negative littermates in part because other re-
ceptors generated by endogenous TCR a rearrangements
were selected. Likewise, the absolute number of peripheral
T cells was not greatly affected in HA16.51 mice and the
percentage of B and T cells in the spleen was similar to that
observed in 6.51HA2 littermates (data not shown). Surpris-
ingly, however, 6.51 cells could be detected in the periph-
ery of the double transgenic mice and the frequency of
splenic 6.51 cells was comparable to that of 6.51HA2 mice
(Fig. 1). There was no evidence for TCR or coreceptor
downregulation among peripheral 6.51 cells from double
transgenic mice that had escaped deletion, but these cells dif-
fered from T cells from 6.51HA2 mice in that they had up-
regulated CD69 and downregulated CD62-L and CD45RB
levels (not shown). When splenic or lymph node T cells
from the double transgenic mice were stimulated in vitro
either with antigen at different concentrations or with the
clonotypic antibody, the 6.51 cells were unresponsive un-
like those from 6.51HA2 mice which proliferated well
without prior immunization (Fig. 2, A and B). There was no
response when cells from normal, non-transgenic BALB/c
mice were stimulated either by antigen or the clonotypic
antibody indicating that 6.51 cells were essential for a pro-
liferative response as well as cytokine production (see be-
low). Addition of IL2 did not restore the response. These
data demonstrate that tolerance in class II restricted cells
can be induced by an antigen expressed in hemopoietic
cells and that the mechanisms may involve deletion of im-
mature cells as well as anergy of peripheral lymphocytes.
The anergy may have in fact been induced after thymic
emigration of the 6.51 cells since at birth we cannot detect
in the thymus HA that can stimulate 6.51 cells in vitro (not
shown).
CD41 Cells Can Be Rendered Tolerant upon Transfer into
Antigen-bearing Recipients. We next addressed the question
whether mature naive CD41 cells, when exposed to high
Figure 2. Proliferative response of lymph node (A) and spleen (B) cells of
double versus single transgenic mice upon antigenic stimulation in vitro.
2 3 105 sIg2 cells were cultured with 5 3 105 irradiated Balb/c spleno-
cytes and stimulated with different doses of peptide (10 and 1 mg/ml),
with coated 6.5 mAb (100 mg/ml) or with medium alone. 3H was added
to the culture 48 h afterwards and left for an additional 18 h. The number
of 6.51 cells per well was determined and proliferation values shown cor-
respond to cpm/ 103 6.51 cells. Values correspond to one set of experi-
ments that included two HA16.51 mice and one HA26.51 mouse. Simi-
lar data were obtained in separate experiments.
Figure 3. Recovery of 6.51 cells after transfer into antigen-positive and
antigen-negative recipients. 2.5 3 106 LN cells from a 6.51/1RAG2/2
mouse were injected i.v. into sublethally irradiated HA1 or HA2 litter-
mates. Recipients were killed at different timepoints and single cell sus-
pensions from lymph nodes and spleen were used for three-color staining.
The absolute number of 6.51 cells recovered from the periphery (lymph
nodes plus spleen) was determined. Values correspond to one set of ex-
periments that included two antigen-positive mice and one antigen-nega-
tive control analyzed at each timepoint. Separate transfer experiments
gave similar results.409 Lanoue et al.
doses of antigen, would follow the same fate as previously
described for CD81 cells (2, 13) . For this purpose, lymph
node cells from RAG2/26.51/1 mice were injected i.v.
into x-irradiated HA1 mice or HA negative littermates and
recipients were analyzed at different time points after trans-
fer. As can be seen in Fig. 3, during the first 4 d 6.51 cells
expanded vigorously upon transfer into antigen-positive re-
cipients and cell numbers declined thereafter. In contrast,
when 6.51 cells were transferred into HA2 recipients, there
was no significant expansion of these cells during the pe-
riod of observation though about five percent of the in-
jected cells could be recovered from these recipients. 6.51
cells recovered at day 4 after transfer into HA-containing
recipients were capable of responding to antigenic stimula-
tion in vitro, though their response was much reduced
when compared to 6.51 naive cells. Curiously, contrary to
6.51 cells from single TCR transgenic mice, the recovered
cells proliferated better upon stimulation with the 6.51
mAb than upon stimulation with the peptide. At 6 or 8 d
after transfer, the remaining 6.51 cells gave an even lower
response than on day 4 to either the peptide or the clono-
typic antibody (Table 1) and their anergic state could not
be reversed by exogenous IL-2. Cells recovered from HA1
recipients at day 4 after transfer were still capable of ex-
panding in vivo when retransferred into another HA1 re-
cipient, while cells recovered 21 d after transfer were no
longer capable of doing so (data not shown). Cytokine pro-
duction by the 6.51 cells recovered at different timepoints
after transfer into antigen-positive recipients was also stud-
ied: IFN-g and IL-4 were produced at significant levels
when cells were stimulated in vitro at early timepoints after
transfer. At day 30 after transfer, no proliferation and no
IFN-g secretion by remaining cells could be detected (data
not shown).
These data thus indicate that class II restricted mature T
cells can undergo deletion or become anergic when ex-
posed to high doses of antigen for longer timepoints. We
next determined whether any of the classical protocols of
inducing tolerance would induce a similarly unresponsive
state of 6.51 cells in situ.
Single Doses of Antigen Applied by Different Routes Do Not
Induce Tolerance. Single doses of oral administration of ei-
ther high or low doses of antigen were reported to induce
tolerance by deletion and anergy, respectively (19, 20, 21).
We therefore fed 6.51 mice with high (1 mg of peptide) or
with low (0.1 mg of HA-Ig) doses of antigen in order to as-
sess the effects of oral feeding on the 6.5 cells. We used low
doses of HA-Ig rather than peptide since in the original
protocols protein antigen rather than peptides were used.
The fed mice were analyzed at different timepoints and
numbers of antigen-specific cells as well as their prolifera-
tive capacity and cytokine secretion were studied. Feeding
with both high and low doses of antigen decreased cell
numbers in thymus and periphery to a certain extent (to
one half), indicating that the orally administered antigen
reached the antigen-specific T cells. Nevertheless, no sig-
nificant effect on cell proliferation or cytokine release could
be observed at any timepoint analyzed. It has also been de-
scribed that oral feeding of antigen shifts the cytokine pro-
duction pattern among the antigen specific cells towards
IL-4, TGF-b, and IL-10 production (12). However, we
observed no decrease in IFN-g production and did not de-
tect significant IL-4 production by 6.51 cells from orally
fed mice when stimulated with antigen in vitro. The ELISA
system that was used can reproducibly detect up to 150 pg/
ml of IL-4 meaning that any shift towards IL4 production
was below that level.
Also administration of soluble antigen given intrave-
nously or intraperitoneally has been reported to induce an-
tigen-specific tolerance (8, 10, 22, 23). We analyzed there-
fore the effect of the similar doses of antigen given by these
routes. Since the injection of 1 mg of peptide was repro-
ducibly lethal at 20–24 h after injection (the same quantity
of peptide injected into non-transgenic mice had no such
effect), we used 0.75 mg of peptide as the highest dose and
0.1 mg of HA-Ig as a lower dose of antigen. Again, we an-
alyzed the numbers of 6.51 cells, as well as their capacity to
proliferate and to produce cytokines. The data shown are
for lymph nodes and were similar with spleen cells. Admin-
istration of both peptide at high doses and HA-Ig at low
doses had a marked effect on numbers of 6.51 thymocytes
at day 3 and on peripheral 6.51 cells at day 6 after injection
(data not shown). The in vitro proliferative response of the
antigen-specific cells at day 6 after injection was reduced by
one half but this was due in most part to the lower percent-
age of 6.51 cells per well. Thus, the functional capacity of
the remaining 6.51 cells was not significantly affected even
6 d after antigen administration, at a point in time when
the number of peripheral antigen-specific cells was decreased
the most.
Table 1. Prolifeeration and Cytokine Production by 6.51 Cells 
Recovered from the Spleen of HA1 Recipients
Days after
transfer
Proliferation
10 mg/ml
peptide
Proliferation
6.5 mAb
IFN-g
production
IL4
production
cpm cpm ng/ml pg/ml
0 2000 6 100 1200 6 94 3.6 0
4 17 6 5 120 6 4 0.8 5.6
6 6 2 59 6 1 1.0 3.9
6 20 6 2 17 6 4 0.6 0.8
25 6 2 14 6 1 1.9 0.7
8 13 6 2 23 6 3 1.6 0
10 6 1 18 6 1 2.0 0.8
14 2 2 ND ND
Values correspond to two recipients for each timepoint, except for day
14, with one recipient. All values were calculated to correspond to the
response of 103 6.51 cells. Proliferation values for unstimulated cells
were lower than 2 cpm per 103 6.51 cells. IFN-g and IL4 values were
determined from the supernatants of the cells stimulated with the 6.5 mAb.410 Tolerance Induction in Mature CD41 Cells
We also injected 6.51 mice with a single dose (0.1 mg)
of deaggregated HA-Ig since it was reported that a single
injection of deaggregated Ig could induce long lasting un-
responsiveness (9). In the transgenic mice, however, such
protocol had no measurable effect.
Responsiveness Is Reduced More Efficiently by HA-Ig than by
Peptide when Given Repeatedly. Because it had been dem-
onstrated that tolerance induction in CD81 cells is depen-
dent on antigen persistence (24, 25), we injected 6.51 mice
i.v. with 0.1 mg of HA-Ig or peptide five times every other
day and analyzed them 6 days after the last injection. The
numbers of 6.51 cells in the thymus and periphery are
shown in Fig. 4 and were markedly decreased in the thy-
mus and in the lymph nodes of treated animals. The de-
crease in lymph nodes was antigen-specific because the
proportion of 6.51 cells among CD41 and CD81 cells was
likewise decreased. Despite the fact that, in terms of molar-
ity, 0.1 mg of the peptide represents at least 2 3 104 more
peptide molecules than 0.1 mg of the HA-Ig, no difference
was observed in their capacity to induce partial deletion or
to decrease the proliferative response of antigen-specific
cells. This could mean that peptide may be very rapidly
cleared upon injection when compared with proteins. Fur-
thermore, the fact that the proteic antigen that contains the
peptide sequence has an Ig-Fc part may facilitate its uptake
and presentation by Fc receptor–bearing APCs. For these
reasons, in all protocols tested hereafter we used the HA-Ig
and not the peptide as source of soluble antigen.
In spite of the prolonged presence of antigen, the re-
maining antigen-specific cells in the periphery were still re-
sponsive to antigenic stimulation in vitro (Fig. 4 c). In addi-
tion, mice treated with the HA-Ig had very big spleens that
contained higher numbers of 6.51 cells when compared to
the control mice or peptide-treated mice. This represents
certainly an undesired effect of protocols aiming to induce
tolerance in mature T cells.
The Combination of CD4 Antibodies and HA-Ig Can Induce
a Transient State of Unresponsiveness. It has been shown by
several groups that administration of CD4 and/or CD8 an-
tibodies can be helpful in the establishment of peripheral
tolerance (26, 27, for review see reference 28). Again, the
precise mechanisms are not known. To study the effect of
CD4 antibodies on responsiveness to HA we adopted a
protocol described by Bushell et al. (29) with the aim of (a)
decreasing CD4 cell numbers and (b) potentially providing
negative signals that may favor the induction of unrespon-
siveness. The CD4 antibody (YTA3.1.2) depleted 60–70%
of peripheral CD4 cells at day 7, as previously described
(18, 29). Mice were injected i.v. with 50 mg of the anti-
body YTA3.1.2 and 1 d later with 50 mg of YTA3.1.2 plus
0.1 mg of HA-Ig. Control mice received either only anti-
gen or only CD4 antibody. Mice were killed at days 3, 7,
and 14 and the number and functional capacity of the 6.51
cells was determined. As can be seen in Fig. 5, combining
anti-CD4 and antigen considerably decreased cell numbers
and induced non-responsiveness in terms of proliferation as
well as of IFN-g production when analyzed 7 d later. At
day 14, the cells began to regain responsiveness. This could
have been due to the fact that newly produced 6.5 cells,
which had not been in contact with antigen, were entering
Figure 4. Effect of repeated
doses of antigen on the number
and function of 6.51 cells. 6.51
mice were injected i.v. with
PBS, 0.1 mg of peptide or 0.1
mg of HA-Ig five times every
other day and were killed 6 d af-
ter the last injection. The abso-
lute numbers of 6.51 cells in the
thymus (A) and lymph nodes (B)
are shown as well as the prolifer-
ation values of lymph node cells
upon antigenic stimulation in
vitro with different peptide doses
(C). Percentages of 6.51 cells
among total T cells are also
shown (D).411 Lanoue et al.
secondary lymphoid tissues from the thymus. This seemed,
however, not to be the case since 6.51 cells from mice
thymectomized before treatment and analyzed 21 d after
treatment also recovered responsiveness. Therefore, the
protocol proved to be efficient in induction, but not in
maintenance of tolerance. It is also clear that anti-CD4 on
its own had an effect on the proliferative capacity of 6.51
cells, suggesting that part of this anergy at that point in time
was not antigen specific. No effect of anti-CD4 alone was
observed in terms of IFN-g production, however, suggest-
ing that the decrease in cytokine production observed at
day 7 in anti-CD4 plus antigen treated mice depended on
Figure 5. Co-administration of
CD4 antibody plus HA-Ig anti-
gen. 6.51 mice received i.v. 50
mg of YTA3.1.2 one day and 50
mg of YTA plus 0.1 mg of HA-
Ig or PBS the next day. Other
mice received antigen (0.1 mg
HA-Ig) alone. Between two and
four mice per group were ana-
lyzed at different timepoints after
treatment. The absolute numbers
of CD416.51 cells in the periph-
ery is shown (CD816.51 cells re-
mained relatively constant). 3H
incorporation is shown for LN
cells stimulated in vitro with 1
mg/ml of peptide (B). The re-
sponse to higher doses of peptide
(10  mg/ml) was similarly de-
creased in treated animals. Prolif-
eration values for day 21 were
obtained from thymectomized
mice (Tx) treated with PBS,
anti-CD4 or anti-CD4/0.1 mg
HA-Ig. Percentages of 6.51 cells
among total T cells were deter-
mined for each mouse (D). IFN-g
values were determined by ELISA
from the supernatant of spleen T
cells stimulated in vitro with 10
mg/ml of peptide (C).
Figure 6. Repeated antigen ad-
ministration in mice previously
treated with anti-CD4 plus anti-
gen. Mice having received 50 mg
of YTA3.1.2 plus 0.1 mg of HA-
Ig 7 d earlier were repeatedly in-
jected i.v. with 0.05, 0.1, or 0.5
mg of HA-Ig. For the first two
doses, four injections were
given every third day. For the
highest dose, two injections were
given, also every third day. Mice
were killed 7 d after the last in-
jection. Control mice received
either PBS or anti-CD4 plus an-
tigen only. Absolute numbers of
6.51 cells in the thymus (A) and
in the periphery (B) are shown.
Proliferation values of sIg2
splenic cells upon in vitro anti-
genic stimulation with peptide
were calculated to correspond to
the response of 103 6.51 cells (C).
Percentages of 6.51 cells among
total T cells are also shown (D).412 Tolerance Induction in Mature CD41 Cells
antigen. Such a decrease in IFN-g was not due to a Th1 to
Th2 shift among the antigen-specific cells since no IL4
production was detected. The lack of an effect of anti-CD4
on IFN-g production and the decreased IFN-g production
after anti-CD4 plus antigen may be due to the fact that an-
tigen is required to stop IFN-g production by the TCR
expressing CD81 T cells.
The Administration of Anti-CD4/HA-Ig Followed by Re-
peated Antigen Administration Can Induce a Long-lasting Anti-
gen-specific Tolerance. Since the above protocol was effi-
cient in inducing unresponsiveness but not in maintaining
it, we reasoned that administering antigen after such treat-
ment in a manner that would favor its persistence could
help to maintain the tolerant state and would render the
treatment more antigen-specific. Therefore, mice treated
7 d earlier with anti-CD4 plus 0.1 mg of HA-Ig received
further injections of antigen. Different doses of HA-Ig
(ranging from 50 to 500 mg) were injected seven days after
treatment with CD4 antibody and 0.1 mg HA-Ig in 3-d
intervals. All mice were analyzed 7 d after the last injection
of antigen. As show in Fig. 6 there was a further reduction
in number of 6.5 cells in an antigen-dose dependent man-
ner in mice that received antigen in addition to the initial
CD4 treatment. Significantly lowering the numbers of
CD41 cells by the CD4 antibody avoided the splenome-
galy that was otherwise seen with repeated doses of HA-Ig.
Likewise, the proliferative capacity of CD41 cells to HA
was reduced in a dose-dependent manner and this reduc-
tion lasted for long periods of time (30 d) in thymecto-
mized mice (data not shown). There was an increase in the
proportion of 6.51CD691 and of 6.51 CD62-L2 cells that
correlated with antigen doses (Fig. 7). The 6.51 cells re-
covered from the mice that repeatedly received either 0.5
or 0.1 mg of HA-Ig secreted very low levels of IFN-g (less
than one-tenth of what was produced by the control mice)
and produced no IL4 (data not shown). It is interesting to
note that while IL4 production was detected after transfer
of 6.5 cells into antigen-bearing recipients (Table 1), it
could not be detected after any of the protocols aiming at
tolerance induction in situ. This difference may be due to
the fact that, upon transfer into antigen-containing recipi-
ents, cells were exposed to much larger doses of antigen
and for a longer period of time.
Discussion
This study was initiated with the aim to analyze the ef-
fect of various protocols that have previously been used to
induce tolerance on CD41 HA-specific T cells with a
transgenic TCR that can be recognized by a monoclonal
antibody. In initial studies, HA antigen was expressed as a
self antigen in the hemopoietic system in HA16.51 double
transgenic mice. 6.51 mature thymocytes were greatly di-
minished presumably because of the deletion of immature
thymocytes. The compartment of CD4181 cells was how-
ever not significantly affected much like it has been ob-
served with superantigen (30) or with TCR transgenic
mice specific for the C5 protein (31). In fact, CD41CD81
cells expressing higher levels of the transgenic TCR that
were present in HA26.51 mice were absent in 6.51HA1
mice (Fig. 1). Surprisingly however, there were a few cells
with the transgenic TCR in the lymph nodes of HA16.51
double transgenic mice and a highly significant number was
found in the spleen of these mice. These cells showed signs
of activation but could not be induced by either antigen or
receptor antibody to proliferate in vitro even in the pres-
ence of exogenous IL2. These cells may represent migrants
from the thymus that escaped deletion there and were an-
ergized in secondary lymphoid organs. The function of
these cells differs from that of CD8lo cells that were de-
tected in the spleen of mice with a class I MHC–restricted
TCR (2, 32) by the fact that these CD41 cells could not be
activated by receptor antibodies. The existence of these au-
toreactive but anergic T cells is of interest and their origin
and migration needs to be addressed in future studies. In
this context it is worthwhile pointing out that in a recent
study, autoreactive T cells were likewise detected in the
periphery of TCR transgenic mice with a class II MHC–
restricted TCR and were causing arthritis in those mice
(33). In the 6.51 HA1 mice we have, however, not seen
any obvious signs of disease.
When mature HA-specific T cells encountered the HA
antigen expressed by hemopoietic cells for the first time af-
ter transfer from 6.51 mice into HA1 recipients, they be-
haved much like mature CD81 T cells that were similarly
exposed to a class I MHC–presented antigen: after an initial
phase of rapid expansion, cells were deleted and the re-
mainder became anergic. The induction of unresponsive-
ness in terms of proliferation and IFN-g production took
several days.
Figure 7. CD69 and CD62-L expression in mice that received repeated
antigen doses after anti-CD4 plus antigen treatment. A two-color staining
was performed on single lymph node cell suspensions. Staining of spleen
cells gave similar results. Histograms represent live cells gated for
6.5int1high expression. Values of CD691 or CD62-L2 cells are given for
both mice that received 2 3 0.5 mg of HA-Ig after anti-CD4/0.1 treat-
ment and are compared to those for mice that received PBS or only the
anti-CD4/0.1 treatment.413 Lanoue et al.
The experiments with mice that express HA-antigen on
hemopoietic cells are relevant with regard to self tolerance
and the transfer experiments with regard to graft versus
host disease for instance after transplantation of allogeneic
bone marrow that contains mature T cells. It would appear
that in the latter case T cells specific for antigens that are
ubiquitously expressed on hemopoietic cells become toler-
ant much like the CD41 cells with the transgenic TCR
when transferred into HA1 recipients, and thus one might
expect that cells which cause late or chronic graft versus
host disease are directed against different antigens. On the
other hand, the depletion of hemopoietic cells before bone
marrow transplantation may interfere with the tolerization
process that is observed in our experiments.
The experiments in mice expressing HA on hemopoietic
cells are obviously of limited relevance for procedures that
aim at the tolerization of T cells in situ with the goal to
prevent or interfere with graft rejection, autoimmunity or
allergy. We therefore tried to develop procedures that
would reliably interfere with the response of a relatively
high frequency of T cells roughly equivalent to that of cells
responding to a foreign MHC haplotype. It may be prima-
rily for this reason that the traditional experimental proto-
cols that were often but not always successful in establish-
ing tolerance to non-MHC antigens failed here. Whether
this is solely due to the relatively high frequency of anti-
gen-specific T cells or to the absence of regulatory T cells
in our TCR transgenic mice is not known. It should, how-
ever, be noted that in our mice the majority of CD41 and
CD81 T cells do not express the transgenic TCR. One
would assume that some of these cells are autoreactive, and
thus, if regulatory T cells have an important role in self tol-
erance they would have to be operative in these TCR
transgenic mice. One may wonder why tolerization failed
even when repeated doses of antigen were given. This
could be due to the fact that cells once exposed to antigen
in a dose insufficient to delete become more resistant to an-
tigen-mediated deletion. Whatever the reason for the fail-
ure of these traditional protocols, we noted that decreasing
the number of antigen-specific T cells by reducing the total
number of CD41 T cells by CD4 antibodies was helpful. It
was under these conditions that the addition of antigen
caused unresponsiveness that could be maintained for long
periods of time if antigen was given repeatedly. Although
we cannot rule out any negative signal delivered by the
CD4 antibodies, the data are certainly consistent with the
notion that the frequency of reactive T cells and the dose
and persistence of antigen are an important parameter de-
termining tolerance. This would be in agreement with a
study by Kearney et al. (15) where tolerance induction of
cells expressing a class II–restricted transgenic TCR was
only achieved after transfer of a small quantity of such cells
into syngeneic non-transgenic recipients even though it is
not clear what influence the transfer procedure had on
these cells. Similarly, a study of Förster et al. (34) indicated
that the ratio of the number of responsive T cells over the
amount of antigen represented a crucial parameter in toler-
ance induction although in their study the antigen may
have been expressed in the thymus.
It is interesting to note that with none of the employed
protocols, be it peptide injection or injection of soluble and
deaggregated protein, feeding of antigen, or giving the an-
tigen together with CD4 antibodies, did we observe either
a complete deletion of antigen specific T cells or a qualita-
tive change in the lymphokine secretion profile of the re-
maining cells in terms of shift from IFN-g secretion to the
production of IL4 as suggested by Zhang et al. (35). So far
we have consistently only been successful with one type of
tolerization protocol, namely shifting the balance between
the frequency of reactive T cells and the dose of antigen in
favor of the latter and observing deletion of cells as well as
induction of anergy.
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